Table of Contents RSS Home Back Issues Indexes
2011 SEPTEMBER–OCTOBER No. 382
October 25, 2011 [posted]

New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI)

The National Heart, Lung, and Blood Institute (NHLBI) issued a new Clinical Alert on October 21, 2011:

Commonly Used Three-drug Regimen for Idiopathic Pulmonary Fibrosis Found Harmful: NIH Stops One Treatment Arm of Trial; Other Two Treatments to Continue

NHLBI has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.

Links to Clinical Alerts/Advisories can also be found from these NLM® Web sites:

New Clinical Alert Issued by National Heart, Lung, and Blood Institute (NHLBI). NLM Tech Bull. 2011 Sep-Oct;(382):e15.

PREVIOUS 2011 SEPTEMBER–OCTOBER No. 382  
Stay Current E-Mail Sign Up Home Back Issues Indexes